Gahan J Pandina

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
    J Clin Psychopharmacol 30:235-44. 2010
  2. ncbi request reprint Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder
    Gahan Pandina
    Janssen Research and Development, LLC, Raritan, NJ 08560, USA
    J Affect Disord 151:384-91. 2013
  3. pmc An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
    Gahan Pandina
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Child Adolesc Psychiatry Ment Health 6:23. 2012
  4. doi request reprint Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder
    Gahan Pandina
    Janssen Research and Development, LLC, Titusville, NJ, USA
    Schizophr Res 143:312-8. 2013
  5. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
  6. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
  7. doi request reprint Cognitive effects of topiramate in migraine patients aged 12 through 17 years
    Gahan J Pandina
    Psychiatry, Johnson and Johnson Pharmaceutical Research and Development L L C, Titusville, New Jersey 08560, USA
    Pediatr Neurol 42:187-95. 2010
  8. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
  9. doi request reprint Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Affect Disord 118:139-46. 2009
  10. ncbi request reprint Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007

Detail Information

Publications19

  1. doi request reprint A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, NJ 08560, USA
    J Clin Psychopharmacol 30:235-44. 2010
    ..6% vs 0.0%), and myalgia (1.0% vs 0.0%). The paliperidone palmitate treatment was efficacious and generally tolerated across the dose range (25, 100, or 150 mg eq.) in adult patients with acutely exacerbated schizophrenia...
  2. ncbi request reprint Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder
    Gahan Pandina
    Janssen Research and Development, LLC, Raritan, NJ 08560, USA
    J Affect Disord 151:384-91. 2013
    ..We assessed the impact of juvenile abuse (emotional, physical, or sexual) on response to treatment in adults with major depressive disorder (MDD) suboptimally responsive to antidepressant therapy...
  3. pmc An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia
    Gahan Pandina
    Janssen Research and Development, LLC, 1125 Trenton Harbourton Road, Titusville, NJ, 08560, USA
    Child Adolesc Psychiatry Ment Health 6:23. 2012
    ..abstract:..
  4. doi request reprint Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder
    Gahan Pandina
    Janssen Research and Development, LLC, Titusville, NJ, USA
    Schizophr Res 143:312-8. 2013
    ..This study explored the relationships among cognitive functioning, clinical symptoms, overall functionality, and demographic characteristics...
  5. pmc A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia
    Danielle Coppola
    Janssen Research and Development, LLC, Raritan, New Jersey, USA
    BMC Psychiatry 12:26. 2012
    ..This study evaluates safety and tolerability, as well as pharmacokinetics, of the highest marketed dose of PP (150 mg eq. [234 mg]) in stable patients with schizophrenia over a 1-year period...
  6. doi request reprint A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Gahan Pandina
    Johnson and Johnson Pharmaceutical Research and Development, LLC, Raritan, New Jersey 08560, USA
    Prog Neuropsychopharmacol Biol Psychiatry 35:218-26. 2011
    ..4 [-1.62;2.38], per-protocol analysis set [primary analysis]). The tolerability and safety of PP was generally similar to RIS-LAI with no new safety or tolerability findings...
  7. doi request reprint Cognitive effects of topiramate in migraine patients aged 12 through 17 years
    Gahan J Pandina
    Psychiatry, Johnson and Johnson Pharmaceutical Research and Development L L C, Titusville, New Jersey 08560, USA
    Pediatr Neurol 42:187-95. 2010
    ..Learning, memory, and executive function were unchanged. The tolerability profile, including cognitive adverse events, appeared to be acceptable...
  8. doi request reprint Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton Harbourton Road, Titusville, NJ 08560, USA
    Int Clin Psychopharmacol 25:51-9. 2010
    ..In conclusion, PaRTS-D may be useful in symptom presence and severity assessments from the patient's perspective and as an adjunctive to other instruments in major depressive disorder diagnosis and response to treatment...
  9. doi request reprint Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ 08560, USA
    J Affect Disord 118:139-46. 2009
    ....
  10. ncbi request reprint Risperidone for treatment-refractory major depressive disorder: a randomized trial
    Ramy A Mahmoud
    Ortho McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA
    Ann Intern Med 147:593-602. 2007
    ..Major depressive disorder has high prevalence, morbidity, and mortality. Inadequate results with antidepressants have prompts addition of a nonstandard treatment (augmentation therapy)...
  11. ncbi request reprint Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 41:68-90. 2008
    ..The Patient-Rated Troubling Symptoms Scale for Anxiety (PaRTS-A) instrument was developed to provide an individualized assessment of patient relevant GAD symptoms...
  12. ncbi request reprint Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA
    Psychopharmacol Bull 40:41-57. 2007
    ....
  13. ncbi request reprint Risperidone and cognitive function in children with disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, New Jersey 08560, USA
    Biol Psychiatry 62:226-34. 2007
    ..Effects of risperidone on cognitive function in children with disruptive behavior disorders (DBDs) and subaverage intelligence quotient (IQ) were assessed...
  14. doi request reprint Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents
    Magali Haas
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA
    J Child Adolesc Psychopharmacol 18:337-45. 2008
    ..The aim of this study was to determine the long-term safety of risperidone as maintenance therapy in children and adolescents with disruptive behavior disorders (DBDs) and normal intelligence...
  15. doi request reprint Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder
    Gahan J Pandina
    Johnson and Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08560, USA
    J Child Adolesc Psychopharmacol 19:749-56. 2009
    ..The aim of this study was to evaluate cognitive effects from long-term risperidone treatment for disruptive behavior disorders (DBDs) in children and adolescents...
  16. ncbi request reprint Direct health care costs for children with pervasive developmental disorders: 1996-2002
    Scott C Flanders
    Regional Outcomes Research, Ortho McNeil Janssen Scientific Affairs, LLC, 740 Waterford Drive, Grayslake, IL 60030, USA
    Adm Policy Ment Health 34:213-20. 2007
    ..1,469 vs. $2,404, respectively, P < 0.0001). Children with PDD incur significantly greater health care costs when compared with children with other chronic pediatric diseases...
  17. ncbi request reprint Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial
    Gahan J Pandina
    Medical Affairs, Janssen Pharmaceutica, Inc, Titusville, NJ 08560, USA
    J Autism Dev Disord 37:367-73. 2007
    ..7.2 (1.4), P<0.05; ES=-0.7]. The most common adverse effect with risperidone was somnolence (74% vs. 7% with placebo). Risperidone treatment was well tolerated and significantly improved behavioral problems associated with autism...
  18. ncbi request reprint Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003
    Scott C Flanders
    Ortho McNeil Janssen Scientific Affairs, L L C, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 17:312-27. 2007
    ..The aim of this study was to compare clinical and health services outcomes in pediatric inpatients prescribed an atypical antipsychotic (AA) to those not prescribed an AA at discharge...
  19. ncbi request reprint Risperidone in the management of disruptive behavior disorders
    Gahan J Pandina
    Medical Affairs Division, Janssen Pharmaceutica Products, L P, Titusville, New Jersey, USA
    J Child Adolesc Psychopharmacol 16:379-92. 2006
    ..As with all antipsychotics, practitioners should monitor young patients' growth, weight, sexual maturation, and metabolic parameters...